General
Preferred name
CEFIXIME
Synonyms
CL-284635 ()
FK-027 ()
FR-17027 ()
Cefiximum ()
Cephoral ()
Cefspan ()
CEFIXIME ANHYDROUS ()
Cefixima, Cefiximum, Cephoral, Cefspan, FR-17027, FK-027, CL-284635 ()
Citropen ()
FK 027 ()
Anhydrous cefixime ()
FR 17027 ()
CL 284,635 ()
Oroken ()
Cefixime hydrate ()
CEFIXIME TRIHYDRATE ()
Suprax ()
P&D ID
PD009856
CAS
79350-37-1
Tags
covalent binder
natural product
drug
available
Approved by
FDA
First approval
1989
Drug Status
investigational
approved
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cefixime is a broad-spectrum, third-generation, orally active cephalosporin antibacterial. (GtoPdb)
Compound Sets
20
AdooQ Bioactive Compound Library
A13697
Cayman Chemical Bioactives
17176
ChEMBL Approved Drugs
CHEMBL1541
ChEMBL Drugs
CHEMBL1541
CovBinderInPDB
CBR002491
CBR002490
Drug Repurposing Hub
DrugBank
DB00671
DrugBank Approved Drugs
DB00671
DrugCentral
537
DrugCentral Approved Drugs
537
DrugMAP
DMY60I8
DrugMAP Approved Drugs
DMY60I8
Guide to Pharmacology
10898
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1541
MedChem Express Bioactive Compound Library
HY-B1381
NCATS Inxight Approved Drugs
XZ7BG04GJX
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
cefixime
TargetMol Bioactive Compound Library
T0932
External IDs
40
Properties
(calculated by RDKit )
Molecular Weight
453.04
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
4
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
1
cLogP
-0.54
TPSA
184.51
Fraction CSP3
0.25
Chiral centers
2.0
Largest ring
6.0
QED
0.23
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
PBPs
antibiotic
Bacterial
Antibiotics,Antineoplastic and Immunosuppressive Antibiotics,Bacterial
Disease Area
infectious disease, otolaryngology, pulmonary
Indication
urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis
MOA
bacterial cell wall synthesis inhibitor
Therapeutic Class
Antibiotics
Source data